Formulation design: New drugs from old

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 537-542

  Crowley, Patrick J ^a   Martini, Luigi G ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AUGMENTIN XR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CIPRO XL; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; GRISEOFULVIN; ITRACONAZOLE; NEW DRUG; PEPTIDE; SCOPOLAMINE; STEROID; TOBRAMYCIN;

AMNESIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED DRUG RELEASE; CREAM; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LOTION; LOW DRUG DOSE; OINTMENT; SIDE EFFECT; TACHYCARDIA; XEROSTOMIA;

EID: 13344283335     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.020     Document Type: Review

References (24)

1. S.L. Lin et al. Preformulation investigation I. Relation of salt forms and biological activity of a novel antihypertensive J. Pharm. Sci. 61 1972 1418-1422
2. L.M. Walmsley et al. Plasma concentrations and relative bioavailability of naftidrofuryl from different salt forms Biopharm. Drug Dis. 7 1986 327-334
3. G.L. Engel et al. Salt form selection and characterisation of LY333531 mesylate monohydrate Int. J. Pharm. 198 2000 239-247
4. R.M. Atkinson et al. Effect of particle size on Griseofulvin blood levels in Man Nature 193 1962 588
5. G.G. Liversedge P. Conzentino Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of Naproxen in rats Int. J. Pharm. 125 1995 309-313
6. J.F. Remenear et al. Crystal engineering of novel crystals of a triazole drug with 1-4-dicarboxylic acids J. Am. Chem. Soc. 125 2003 8456-8457
7. T.R. Bates J.A. Sequira Bioavailability of micronised griseofulvin from corn oil-in-water emulsion, aqueous suspension and commercial tablet dosage forms J. Pharm. Sci. 64 1975 793-797
8. N.J. Brown et al. Characteristics of lipid substances activating the ileal brake in the rat Gut 31 1990 1126-1129
9. J.N. Hunt M.T. Knox The slowing of gastric emptying by four strong acids and three weak acids J. Physiol. 222 1972 187-208
10. Muranishi, S. (1991) Drug targeting towards lymphatics. In Advances in Drug Research (Vol. 21), pp. 1-37, Academic Press
11. C.H. Porter et al. Lymphatic transport of halofantrine in the triple-cannulated anaesthetized rat model: Effect of lipid vehicle dispersion J. Pharm. Sci. 85 1996 351-361
12. B.J. Aungst Intestinal permeation enhancers J. Pharm. Sci. 89 2000 429-442
13. W. Curatolo Physical and chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Technol. Today 1 1998 387-392
14. R.B. Kim Transporters and drug disposition Curr. Opin. Drug Discov. Dev. 3 2000 94-101
15. S.K. Hukkinen et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice Clin. Pharmacol. Ther. 58 1995 127-131
16. D.J. Edwards et al. Identification of 6′7′-dihydroxybergamotin, a cytochrome P450 Inhibitor in grapefruit juice Drug Metab. Dispos. 24 1996 1287-1290
17. J. Shaw Development of transdermal therapeutic systems Drug Dev. Ind. Pharm. 9 1983 579-603
18. J.M. Blondeau Current issues in the management of urinary tract infections: Extended-release ciprofloxacin as a novel treatment option Drugs 64 2004 611-628
19. D.A. Talan et al. Extended-release Ciprofloxacin (Cipro XR) for treatment of urinary tract infections Int. J. Antimicrob. Agents 23 Suppl. 1 2004 S54-S66
20. M.J.M. Darkes C.M. Perry Clarithromycin extended-release tablet: Review of its use in the management of respiratory tract infections Am. J. Respir. Med. 2 2003 175-201
21. G. Drusano Role of pharmacokinetics in the outcome of infections Antimicrob. Agents Chemother. 32 1988 289-297
22. G. Woodnutt V. Berry Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae Antimicrob. Agents Chemother. 43 1999 29-34
23. C.M. Kaye et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced amoxicillin/clavulanate formulation Clin. Ther. 23 2001 578-584
24. H.A.E. Benson R.J. Prankerd Optimization of drug delivery III sustained/controlled-release oral drug delivery Aust. J. Hosp. Pharm. 27 1997 381-389